• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1245256 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
+ W, t1 {3 e5 G. kNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
, t6 r) ^  B: g1 l9 H+ Author Affiliations
0 F) C0 P# ~  a. P! j; O2 S
# l4 l4 t; @) w2 F+ ~1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan * w* m1 ]" c# G' Z
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
! S. T4 W4 a  p: f3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
2 C0 V5 ?! e. g8 @, r4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 1 P% r+ O8 |8 k, T  `' h
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
/ c' H. @) K) d3 l7 d6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
  m  M% \9 J1 z7 g( S5 O2 O: ^7Kinki University School of Medicine, Osaka 589-8511, Japan   u" a. ?! E8 o/ W
8Izumi Municipal Hospital, Osaka 594-0071, Japan * k( t1 u9 @; x; u5 L+ Z% p" K3 \
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
2 g6 v5 m2 N; c$ tCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
) t) J# H* y+ D3 t; [AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
" B/ H; Y$ T/ `( T0 V( H! j, }! B% n1 p' ?9 W6 A
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
9 P% E9 W% V6 g' |7 ?! t1 S# w) t  ]% Y
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato 3 ]9 Y0 ?' H* O7 o3 D# s
7 F/ d! {- L0 _6 t! _2 V* ~# Q
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  4 ^: ^( U* k# b: \7 g% ~; y

. d  B- \; r: D: \Published online on: Thursday, December 1, 2011
+ Z" `1 _- {1 Y* h5 ^+ }  I* X9 q7 p% {/ h. X. a3 ^2 j
Doi: 10.3892/ol.2011.507 ; W3 n! W& H, W; W* h! f" V  m6 t0 [0 ~

8 [! d) }) i% c3 r/ VPages: 405-410
0 i% w4 v* @* f& k
/ c8 ~3 c/ F9 ]( E) x5 E  }Abstract:! s1 }+ ]. p1 S* }" c/ W
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
; u# ~" F# ?4 q7 g5 r . x1 f6 x* p4 v9 X& E! g
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
, g; C' `% O, {5 e8 m% ]) k1 gF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
. n2 T6 F  r- t( W, T$ V/ A+ Author Affiliations/ [9 P6 W6 e8 t+ |3 w
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu ! L" B6 y0 q; X( s  E
2Department of Thoracic Surgery, Kyoto University, Kyoto
6 G' S2 s9 [* |3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
; G" c5 s! T8 P8 [7 C&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
- s% F3 {' @3 r) Q5 yReceived September 3, 2010.
8 [7 c9 C2 t3 j. Z5 {; @5 C* mRevision received November 11, 2010. ; J! a& X' x* a; x8 b
Accepted November 17, 2010.
; m0 [7 Z2 E2 s9 c# N) nAbstract
  |8 L2 ?- a6 [$ }) z0 JBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. $ M( `; k' K4 y0 T$ ]/ j- v" w
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. / C; P9 h% d0 i, p# n; p
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
) D7 w  |4 Q: @$ }Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. ! R4 [8 @0 Z1 I) @: p& V+ r+ r
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
9 _) x! W7 H  c' v今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?; T' J" B, i/ x2 s9 {  ]" n2 V
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
" G" F( }: F8 Q& a9 j% J9 k7 {* ahttp://clinicaltrials.gov/ct2/show/NCT01523587
+ X  A5 t( h' |5 A. E0 u+ {1 {4 v& V% I6 g
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC$ l4 O3 @$ Y: n* e8 l( z( s* ~
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 : T8 M( h1 m  F+ W  u- C( g  |
. i* t6 E: x$ x5 q4 `8 p/ e+ r
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
9 y$ }9 I) l2 K  H) Z! D8 }7 g至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
+ e# V0 z! p% X: h. S% g7 f
没有副作用是第一追求,效果显著是第二追求。
( m3 T( z; q# `  T9 n& T4 o不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表